Core Viewpoint - Junshi Biosciences is actively developing a monkeypox recombinant protein vaccine in collaboration with several prestigious institutions, indicating a strong focus on innovative vaccine development and a commitment to expanding its product pipeline in the biopharmaceutical sector [2][3]. Group 1: Company Developments - On October 27, 2023, Junshi Biosciences announced a partnership with Peking University, the Institute of Microbiology of the Chinese Academy of Sciences, Shanxi Advanced Innovation Research Institute, and Beihang University to jointly develop a monkeypox recombinant protein vaccine [2]. - The company’s subsidiary, Junshi Biotech, is involved in the development of various vaccine-related products, including monkeypox and Zika vaccines, which are currently in the preclinical development stage [2]. - Junshi Biosciences has a complete industry chain capability from drug discovery and development to global clinical research, large-scale production, and commercialization, aiming to become a leading innovative pharmaceutical company [3]. Group 2: Product Pipeline and Achievements - Junshi's core product, Toripalimab, is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review, showcasing its market potential [3]. - The company has also developed Tifcemalimab, the world's first anti-BTLA monoclonal antibody entering clinical development, with ongoing Phase III clinical trials and multiple Phase Ib/II studies in various tumor types [3]. - Junshi is exploring early-stage pipelines, with several products expected to initiate key registration clinical trials by 2025 [3]. Group 3: Financial Performance - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a 35.72% year-on-year growth [9]. - The company’s main business revenue composition includes 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services and others [9]. Group 4: Market Position and Shareholder Information - As of September 30, 2025, Junshi Biosciences had 35,900 shareholders, an increase of 15.17% from the previous period, with an average of 21,361 circulating shares per person, a decrease of 12.96% [9]. - The company is part of the pharmaceutical and biotechnology sector, focusing on biopharmaceuticals and virus prevention, with significant involvement in monkeypox and COVID-19 related products [9].

Group 1 - The core viewpoint of the news is that Junshi Biosciences has experienced a decline in stock price and significant net outflow of funds, indicating potential investor concerns [1][2]. - As of February 26, Junshi Biosciences' stock price dropped by 2.01% to 34.05 CNY per share, with a total market capitalization of 34.959 billion CNY [1]. - The company has seen a year-to-date stock price decrease of 0.32%, with a 5-day decline of 2.80%, a 20-day decline of 3.40%, and a 60-day decline of 6.07% [2]. Group 2 - Junshi Biosciences, established on December 27, 2012, specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [2]. - As of September 30, 2025, the company reported a revenue of 1.806 billion CNY, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million CNY, reflecting a year-on-year growth of 35.72% [2]. - The company is categorized under the pharmaceutical and biotechnology industry, specifically in the bioproducts sector, and is involved in various concepts including monkeypox, exclusive drugs, COVID-19 medications, and virus prevention [2]. Group 3 - As of September 30, 2025, the number of shareholders for Junshi Biosciences increased by 15.17% to 35,900, while the average circulating shares per person decreased by 12.96% to 21,361 shares [2]. - Among the top ten circulating shareholders, E Fund's SSE STAR 50 ETF holds 19.3929 million shares, a decrease of 2.8203 million shares from the previous period, while Huaxia's SSE STAR 50 ETF holds 18.9720 million shares, down by 1.0745 million shares [3].

Group 1 - The core viewpoint of the news is that Junshi Biosciences has experienced fluctuations in its stock price and trading volume, with a recent increase of 2.10% in its share price, reaching 34.99 CNY per share, and a total market capitalization of 35.92 billion CNY [1] - As of February 25, the stock has seen a year-to-date increase of 2.43%, but has declined by 2.04% over the last five trading days, 0.85% over the last twenty days, and 2.13% over the last sixty days [2] - Junshi Biosciences, established on December 27, 2012, specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [2] Group 2 - As of September 30, 2025, Junshi Biosciences reported a revenue of 1.806 billion CNY, reflecting a year-on-year growth of 42.06%, while the net profit attributable to shareholders was -596 million CNY, showing a year-on-year increase of 35.72% [2] - The company is categorized under the pharmaceutical and biotechnology industry, specifically in the biopharmaceutical sector, and is involved in various concept sectors including monkeypox, exclusive drugs, COVID-19 medications, and virus prevention [2] - Institutional holdings show that as of September 30, 2025, the top ten circulating shareholders include E Fund's SSE STAR 50 ETF and Huaxia's SSE STAR 50 Component ETF, both of which have reduced their holdings compared to the previous period [3]

Market Overview - On May 30, the three major A-share indices collectively declined, with the Shanghai Composite Index falling by 0.47% to 3347.49 points, the Shenzhen Component Index down by 0.85% to 10040.63 points, and the ChiNext Index decreasing by 0.96% to 1993.19 points [1]. Fund Manager Changes - In the past 30 days (April 30 to May 30), a total of 513 fund managers have left their positions across various funds. On May 30 alone, 39 funds announced changes in fund managers, with 6 leaving due to job changes and 2 due to personal reasons [1]. - Notable fund managers who left include those managing a total of 15 funds and 24 funds respectively, indicating significant turnover that could impact fund performance [1]. New Fund Managers - New fund managers have taken over several funds, including Yan Peixian at China Europe Fund, managing assets totaling 12.365 billion yuan, with a notable return of 87.82% over 10 years and 49 days on the China Europe Pure Bond One Year A fund [3]. - Other new appointments include managers for the China Europe Xingyue Bond A and C funds, as well as the China Europe Xingying One Year Open Bond Initiation fund [3]. Fund Research Activity - In the last month, Huaxia Fund conducted the most company research, engaging with 67 listed companies, followed by Bosera Fund with 62 and Harvest Fund with 60 [5]. - The most researched industry was specialized equipment, with 278 instances of fund company inquiries, followed by the medical device sector with 210 inquiries [5]. Individual Stock Research - The most researched stock in the past month was Zhaowei Electromechanical, with 88 fund management companies participating in the research, followed by Anji Technology and Heng'erda with 82 and 80 respectively [6]. - In the past week (May 23 to May 30), Huafeng Technology led with 33 fund institutions conducting research, followed by Jucheng Co., Kexing Pharmaceutical, and Aisen Co. with 27, 24, and 17 respectively [6].